deltatrials
Completed PHASE2 NCT00034203

Safety and Efficacy of a Monoclonal Antibody for Treatment of Rheumatoid Arthritis.

Sponsor: XOMA (US) LLC

Conditions Rheumatoid Arthritis
Interventions efalizumab
Updated 6 times since 2017 Last updated: Jun 23, 2005 Started: Apr 30, 2002 Completion: Aug 31, 2003

This PHASE2 trial investigates Rheumatoid Arthritis and is currently completed. XOMA (US) LLC leads this study, which shows 6 recorded versions since 2002 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Apr 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • XOMA (US) LLC
Data source: XOMA (US) LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amarillo, United States, Austin, United States, Birmingham, United States, Boston, United States, Brooklyn, United States, Clearwater, United States, Cooperstown, United States, Decatur, United States, Des Moines, United States, Duncansville, United States and 40 more location s